| Assay Name | Tissue | Organism | Target Gene ID | Target HGNC Symbol | Response | AC50 Value |
|---|
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Activatory | 3.95 μM |
| ATG_DR4_LXR_CIS | Liver | Human | 7376|10062 | NR1H2|NR1H3 | Activatory | 4.23 μM |
| ATG_E2F_CIS | Liver | Human | 1869 | E2F1 | Activatory | 11.1 μM |
| ATG_EGR_CIS | Liver | Human | 1958 | EGR1 | Activatory | 8.48 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 3.53 μM |
| ATG_HNF6_CIS | Liver | Human | 3175 | ONECUT1 | Inhibitory | 11.1 μM |
| ATG_IR1_CIS | Liver | Human | 9971 | NR1H4 | Activatory | 7.35 μM |
| ATG_VDRE_CIS | Liver | Human | 7421 | VDR | Inhibitory | 13.08 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 3.15 μM |
| ATG_FXR_TRANS | Liver | Human | 9971 | NR1H4 | Gain | 13.49 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 6.2 μM |
| ATG_RXRb_TRANS | Liver | Human | 6257 | RXRB | Gain | 7.55 μM |
| NVS_ADME_hCYP2B6 | | Human | 1555 | CYP2B6 | Loss | 1.02 μM |
| NVS_ADME_hCYP2C19 | | Human | 1557 | CYP2C19 | Loss | 0.37 μM |
| NVS_ENZ_hMMP7 | | Human | 4316 | MMP7 | Loss | 5.52 μM |
| NVS_GPCR_h5HT7 | | Human | 3363 | HTR7 | Loss | 1.04 μM |
| NVS_GPCR_hAdoRA2a | | Human | 135 | ADORA2A | Loss | 0.11 μM |
| NVS_GPCR_hAdrb1 | | Human | 153 | ADRB1 | Loss | 0.98 μM |
| NVS_GPCR_hOpiate_mu | | Human | 4988 | OPRM1 | Loss | 1.08 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.19 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.36 μM |
| NVS_TR_hNET | | Human | 6530 | SLC6A2 | Loss | 0.85 μM |
| BSK_3C_Eselectin | Vascular | Human | 6401 | SELE | Inhibitory | 11.68 μM |
| BSK_3C_HLADR | Vascular | Human | 3122 | HLA-DRA | Inhibitory | 8.22 μM |
| BSK_3C_ICAM1 | Vascular | Human | 3383 | ICAM1 | Inhibitory | 10.76 μM |
| BSK_3C_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 9.53 μM |
| BSK_3C_MIG | Vascular | Human | 4283 | CXCL9 | Inhibitory | 11.38 μM |
| BSK_3C_TissueFactor | Vascular | Human | 2152 | F3 | Inhibitory | 7.03 μM |
| BSK_3C_uPAR | Vascular | Human | 5329 | PLAUR | Inhibitory | 7.26 μM |
| BSK_3C_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 10.18 μM |
| BSK_4H_Eotaxin3 | Vascular | Human | 10344 | CCL26 | Inhibitory | 10.38 μM |
| BSK_4H_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 8.77 μM |
| BSK_4H_Pselectin | Vascular | Human | 6403 | SELP | Inhibitory | 10.91 μM |
| BSK_4H_uPAR | Vascular | Human | 5329 | PLAUR | Inhibitory | 9.73 μM |
| BSK_4H_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 8.34 μM |
| BSK_4H_VEGFRII | Vascular | Human | 3791 | KDR | Inhibitory | 6.61 μM |
| BSK_BE3C_HLADR | Lung | Human | 3122 | HLA-DRA | Inhibitory | 7.65 μM |
| BSK_BE3C_IL1a | Lung | Human | 3552 | IL1A | Inhibitory | 9.67 μM |
| BSK_BE3C_IP10 | Lung | Human | 3627 | CXCL10 | Inhibitory | 7.91 μM |
| BSK_BE3C_MIG | Lung | Human | 4283 | CXCL9 | Inhibitory | 9.37 μM |
| BSK_BE3C_MMP1 | Lung | Human | 4312 | MMP1 | Inhibitory | 10.36 μM |
| BSK_BE3C_PAI1 | Lung | Human | 5054 | SERPINE1 | Inhibitory | 8.29 μM |
| BSK_BE3C_TGFb1 | Lung | Human | 7040 | TGFB1 | Inhibitory | 7.05 μM |
| BSK_BE3C_tPA | Lung | Human | 5327 | PLAT | Inhibitory | 3.0 μM |
| BSK_BE3C_uPA | Lung | Human | 5328 | PLAU | Inhibitory | 5.32 μM |
| BSK_BE3C_uPAR | Lung | Human | 5329 | PLAUR | Inhibitory | 6.12 μM |
| BSK_CASM3C_LDLR | Vascular | Human | 3949 | LDLR | Inhibitory | 10.6 μM |
| BSK_hDFCGF_CollagenIII | Skin | Human | 1281 | COL3A1 | Inhibitory | 3.45 μM |
| BSK_hDFCGF_EGFR | Skin | Human | 1956 | EGFR | Inhibitory | 2.09 μM |
| BSK_hDFCGF_IL8 | Skin | Human | 3576 | CXCL8 | Inhibitory | 13.35 μM |
| BSK_hDFCGF_IP10 | Skin | Human | 3627 | CXCL10 | Inhibitory | 4.02 μM |
| BSK_hDFCGF_PAI1 | Skin | Human | 5054 | SERPINE1 | Inhibitory | 8.22 μM |
| BSK_hDFCGF_VCAM1 | Skin | Human | 7412 | VCAM1 | Inhibitory | 4.35 μM |
| BSK_KF3CT_IP10 | Skin | Human | 3627 | CXCL10 | Inhibitory | 11.48 μM |
| BSK_KF3CT_MMP9 | Skin | Human | 4318 | MMP9 | Inhibitory | 8.52 μM |
| BSK_KF3CT_TGFb1 | Skin | Human | 7040 | TGFB1 | Inhibitory | 6.14 μM |
| BSK_KF3CT_uPA | Skin | Human | 5328 | PLAU | Inhibitory | 11.13 μM |
| BSK_LPS_CD40 | Vascular | Human | 958 | CD40 | Inhibitory | 7.66 μM |
| BSK_LPS_Eselectin | Vascular | Human | 6401 | SELE | Inhibitory | 11.11 μM |
| BSK_LPS_IL1a | Vascular | Human | 3552 | IL1A | Inhibitory | 7.55 μM |
| BSK_LPS_IL8 | Vascular | Human | 3576 | CXCL8 | Inhibitory | 13.65 μM |
| BSK_LPS_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 10.66 μM |
| BSK_LPS_MCSF | Vascular | Human | 1435 | CSF1 | Inhibitory | 10.64 μM |
| BSK_LPS_PGE2 | Vascular | Human | 5732 | PTGER2 | Inhibitory | 9.92 μM |
| BSK_LPS_TissueFactor | Vascular | Human | 2152 | F3 | Inhibitory | 12.03 μM |
| BSK_LPS_TNFa | Vascular | Human | 7124 | TNF | Inhibitory | 11.56 μM |
| BSK_LPS_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 9.57 μM |
| BSK_SAg_CD38 | Vascular | Human | 952 | CD38 | Inhibitory | 7.7 μM |
| BSK_SAg_CD40 | Vascular | Human | 958 | CD40 | Inhibitory | 8.7 μM |
| BSK_SAg_CD69 | Vascular | Human | 969 | CD69 | Inhibitory | 8.18 μM |
| BSK_SAg_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 11.25 μM |
| BSK_SAg_MIG | Vascular | Human | 4283 | CXCL9 | Inhibitory | 10.58 μM |
| ATG_DR4_LXR_CIS | Liver | Human | 7376|10062 | NR1H2|NR1H3 | Inhibitory | 2.8 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 1.02 μM |
| ATG_MRE_CIS | Liver | Human | 4520 | MTF1 | Inhibitory | 3.58 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Inhibitory | 1.45 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.67 μM |
| ATG_FXR_TRANS | Liver | Human | 9971 | NR1H4 | Gain | 8.41 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 3.71 μM |
| ATG_THRa1_TRANS | Liver | Human | 7067 | THRA | Gain | 4.85 μM |
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Activatory | 3.58 μM |
| ATG_E_Box_CIS | Liver | Human | 7391 | USF1 | Inhibitory | 5.25 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Activatory | 0.76 μM |
| ATG_MRE_CIS | Liver | Human | 4520 | MTF1 | Activatory | 3.58 μM |
| ATG_NRF2_ARE_CIS | Liver | Human | 4780 | NFE2L2 | Activatory | 6.04 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Activatory | 0.93 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.62 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 2.07 μM |
| ATG_RXRb_TRANS | Liver | Human | 6257 | RXRB | Gain | 2.65 μM |
| ATG_E_Box_CIS | Liver | Human | 7391 | USF1 | Activatory | 5.67 μM |
| ATG_ERE_CIS | Liver | Human | 2099 | ESR1 | Inhibitory | 0.6 μM |
| ATG_GLI_CIS | Liver | Human | 2735 | GLI1 | Inhibitory | 3.58 μM |
| ATG_GRE_CIS | Liver | Human | 2908 | NR3C1 | Inhibitory | 5.27 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Inhibitory | 1.16 μM |
| ATG_Sox_CIS | Liver | Human | 6656 | SOX1 | Inhibitory | 5.49 μM |
| ATG_Sp1_CIS | Liver | Human | 6667 | SP1 | Inhibitory | 5.85 μM |
| ATG_STAT3_CIS | Liver | Human | 6774 | STAT3 | Inhibitory | 5.58 μM |
| ATG_ERa_TRANS | Liver | Human | 2099 | ESR1 | Gain | 0.76 μM |
| ATG_FXR_TRANS | Liver | Human | 9971 | NR1H4 | Gain | 4.29 μM |
| NVS_ADME_hCYP2C9 | | Human | 1559 | CYP2C9 | Loss | 0.49 μM |
| NVS_ADME_rCYP2C11 | | Rat | 29277 | Cyp2c11 | Loss | 0.25 μM |
| NVS_ADME_rCYP3A2 | | Rat | 266682 | Cyp3a2 | Loss | 1.1 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.29 μM |
| NVS_ADME_hCYP2B6 | | Human | 1555 | CYP2B6 | Loss | 4.09 μM |
| NVS_ADME_hCYP2C18 | | Human | 1562 | CYP2C18 | Loss | 0.51 μM |
| NVS_ADME_hCYP2C19 | | Human | 1557 | CYP2C19 | Loss | 1.43 μM |
| NVS_ADME_hCYP2C9 | | Human | 1559 | CYP2C9 | Loss | 2.8 μM |
| NVS_ADME_rCYP2B1 | | Rat | 24300 | Cyp2b1 | Loss | 5.96 μM |
| NVS_ADME_rCYP2C11 | | Rat | 29277 | Cyp2c11 | Loss | 1.16 μM |
| NVS_ADME_rCYP2C6 | | Rat | 293989 | Cyp2c6 | Loss | 5.13 μM |
| NVS_ADME_rCYP3A1 | | Rat | 25642 | Cyp3a23-3a1 | Loss | 3.66 μM |
| NVS_ADME_rCYP3A2 | | Rat | 266682 | Cyp3a2 | Loss | 7.08 μM |
| NVS_GPCR_hOpiate_mu | | Human | 4988 | OPRM1 | Loss | 2.66 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 4.61 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.99 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.72 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 0.62 μM |
| NVS_TR_hNET | | Human | 6530 | SLC6A2 | Loss | 1.81 μM |
| NVS_ADME_hCYP2B6 | | Human | 1555 | CYP2B6 | Loss | 1.57 μM |
| NVS_ADME_hCYP2C19 | | Human | 1557 | CYP2C19 | Loss | 0.45 μM |
| NVS_ADME_hCYP2C9 | | Human | 1559 | CYP2C9 | Loss | 0.07 μM |
| NVS_ADME_rCYP2B1 | | Rat | 24300 | Cyp2b1 | Loss | 1.59 μM |
| NVS_ADME_rCYP2C11 | | Rat | 29277 | Cyp2c11 | Loss | 0.19 μM |
| NVS_ADME_rCYP2C6 | | Rat | 293989 | Cyp2c6 | Loss | 7.93 μM |
| NVS_ADME_rCYP3A1 | | Rat | 25642 | Cyp3a23-3a1 | Loss | 6.55 μM |
| NVS_ADME_rCYP3A2 | | Rat | 266682 | Cyp3a2 | Loss | 2.71 μM |
| NVS_GPCR_hOpiate_mu | | Human | 4988 | OPRM1 | Loss | 1.63 μM |
| NVS_NR_hER | | Human | 2099 | ESR1 | Loss | 0.01 μM |
| NVS_NR_hGR | | Human | 2908 | NR3C1 | Loss | 0.84 μM |
| NVS_NR_mERa | | Mouse | 13982 | Esr1 | Loss | 0.34 μM |
| NVS_NR_rAR | Prostate | Rat | 24208 | Ar | Loss | 2.18 μM |
| NVS_TR_hNET | | Human | 6530 | SLC6A2 | Loss | 1.57 μM |
| ATG_hERa_XSP1 | Liver | Human | 2099 | ESR1 | Gain | 0.66 μM |
| CCTE_GLTED_hDIO3 | | Human | 1735 | DIO3 | Loss | 4.51 μM |
| ATG_hERa_XSP2 | Liver | Human | 2099 | ESR1 | Gain | 0.53 μM |
| ATG_hTRb_XSP2 | Liver | Human | 7068 | THRB | Gain | 10.0 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | Human | 2099 | ESR1 | Gain | 12.56 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 9.22 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 3.18 μM |
| TOX21_PXR_LUC_Agonist | Liver | Human | 8856 | NR1I2 | Gain | 12.28 μM |
| TOX21_p450_CYP3A4_Antagonist | | Human | 1576 | CYP3A4 | Loss | 3.12 μM |
| TOX21_p450_CYP2C19_Antagonist | | Human | 1557 | CYP2C19 | Loss | 1.04 μM |
| TOX21_p450_CYP2C9_Antagonist | | Human | 1559 | CYP2C9 | Loss | 5.38 μM |
| TOX21_hERG_U2OS_Antagonist | Bone | Human | 3757 | KCNH2 | Loss | 11.21 μM |
| TOX21_ERa_BLA_Agonist_ratio | Kidney | Human | 2099 | ESR1 | Gain | 13.31 μM |
| TOX21_ERa_LUC_VM7_Agonist | Breast | Human | 2099 | ESR1 | Gain | 11.46 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | Human | 2908 | NR3C1 | Loss | 9.13 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 11.82 μM |
| TOX21_AP1_BLA_Agonist_ratio | Cervix | Human | 2353|3725 | FOS|JUN | Gain | 12.88 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 4.59 μM |
| TOX21_PXR_LUC_Agonist | Liver | Human | 8856 | NR1I2 | Gain | 12.08 μM |
| TOX21_p450_CYP3A4_Antagonist | | Human | 1576 | CYP3A4 | Loss | 3.63 μM |
| TOX21_p450_CYP2C19_Antagonist | | Human | 1557 | CYP2C19 | Loss | 1.31 μM |
| TOX21_p450_CYP2C9_Antagonist | | Human | 1559 | CYP2C9 | Loss | 6.55 μM |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.